Compare Ascendis Pharma A/S (ASND) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Charles Schwab Corporation Common Stock — how do they compare? Ascendis Pharma A/S trades at $257 (market cap $16.67B), while Charles Schwab Corporation Common Stock trades at $109.34 (market cap $186.25B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 11.2× Ascendis Pharma A/S's market cap, and Charles Schwab Corporation Common Stock pays a 1.19% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | SCHW | |
|---|---|---|
Market Cap | $16.67B | $186.25B |
Sector | Health | Financials |
52-Week High | $277.18 | $108.02 |
52-Week Low | $189.74 | $85.35 |
Enterprise Value | $17.04B | — |
Dividend Yield | — | 1.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.46, showing minimal daily movement (-0.06%). The stock maintains a bullish technical outlook with strong analyst support (92% buy ratings) and a consensus price target of $309.75, representing 21% upside potential. Recent developments include positive clinical trial updates for TransCon CNP in achondroplasia and inclusion in multiple Russell indexes, signaling growing institutional recognition. Revenue growth has been robust, increasing from $51M in 2022 to $720M in 2025, though the company remains unprofitable with a net loss of $228M in 2025.
ASND presents a growth investment opportunity with multiple product catalysts and improving financial trajectory, though significant risks remain. The company's premium valuation (P/E 29.05, P/S 15.68) reflects high growth expectations, while negative shareholder equity and substantial debt require careful monitoring. Positive cash flow generation since 2024 and upcoming regulatory milestones provide potential upside, but execution risks and clinical trial outcomes could impact shareholder value.
Charles Schwab (SCHW) trades at $109.28, up 1.19% today, near its all-time high of $109.05 (Zacks Investment Research, 2026-08-07). The stock shows strong momentum with bullish technical signals and consistent earnings beats in recent quarters. Revenue grew to $23.92 billion in 2025, with net income margin expanding to 37%, while analyst consensus is bullish with a $122.33 price target. Recent news highlights insider selling and ongoing litigation, but institutional acquisitions signal confidence.
Outlook remains positive driven by earnings growth and market share gains, but risks include regulatory scrutiny from lawsuits (Business Wire, 2026-08-10) and interest rate sensitivity. The stock offers upside to consensus targets, though overbought conditions suggest potential near-term volatility. Investors should weigh robust fundamentals against macroeconomic and legal headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
